Insilico Medicine – a generative artificial intelligence (AI)-driven clinical-stage drug discovery company – nominated the preclinical candidate of an inhalation solution for ISM001-055, which is the first anti-fibrotic small molecule inhibitor developed leveraging its proprietary AI drug discovery platform Pharma.AI for the treatment of Idiopathic Pulmonary Fibrosis (IPF). And with promising preclinical results, Insilico is proceeding with IND filing as the first AI drug discovery company to venture into nebulized formulations.
The administration by inhalation is a complex drug delivery technology that requires combining formulation and devices, presenting higher technical barriers. Inhalation solutions deliver treatment as vapor or aerosol through special devices into the respiratory tract (i.e., the target organ), which is considered one of the most efficient routes of drug delivery as it may provide advantages including rapid action onset, high bioavailability, and lowered effective dose—and reduced side effects with a noninvasive and targeted route of administration.
In preclinical studies, the inhalation solution of ISM001-055 achieved higher lung exposure with low systemic exposure and demonstrated antifibrotic and anti-inflammatory efficacy in animal models. Moreover, it showed good pharmacokinetic (PK) and safety profiles and good stability and solubility.
Powered by Pharma.AI, the Company’s proprietary AI drug discovery platform across biology, chemistry and clinical development, Insilico has developed a comprehensive portfolio comprising 30+ pipelines and covering 29 targets, with three currently in the clinical stage. In addition to this inhaled solution which intersects pharmacology, particle dynamics, and nebulizer design, Insilico continues to explore integrating advanced technologies into its proprietary Pharma.AI platform, including quantum computing, multimodal transformer technology, and large language models.
KEY QUOTES:
“I am thrilled to see the announcement of inhalation solution for ISM001-055, which is a remarkable milestone for a novel drug candidate, as 99% of programs fail at the preclinical stage. With the support of Pharma.AI driven by generative artificial intelligence, we are making drug discovery more efficient and more accurate, which is proved by the three programs in the clinical stage.”
— Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine
“Here at Insilico, innovation never stops, and that means multidimensional validation of our AI platform capabilities, for various disease areas, indications and formunlations. We hope to proceed the inhalation formulation of ISM001-055 to clinic as soon as possible to address unmet clinical needs.”
— Feng Ren, Ph.D., Co-CEO and CSO of Insilico Medicine
